Evidence map›Paper›PMID 35604111›Full record

ArticleJournal of materials chemistry. B2022

Linear and branched polymer prodrugs of the water-soluble nucleoside reverse-transcriptase inhibitor emtricitabine as structural materials for long-acting implants.

Anika Shakil, Faye Y Hern, Chung Liu, Kartik Temburnikar, Pierre Chambon, Neill Liptrott, Tom O McDonald, Megan Neary, Andrew Owen, Caren Freel Meyers and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of materials chemistry. B, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Anika ShakilDepartment of Chemistry, University of Liverpool, Crown Street, Liverpool, L69 7ZD, UK. srannard@liverpool.ac.uk.
Faye Y HernDepartment of Chemistry, University of Liverpool, Crown Street, Liverpool, L69 7ZD, UK. srannard@liverpool.ac.uk.
Chung LiuDepartment of Chemistry, University of Liverpool, Crown Street, Liverpool, L69 7ZD, UK. srannard@liverpool.ac.uk.
Kartik TemburnikarDepartment of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, 725 North Wolfe St., Baltimore, MD, 21205, USA.
Pierre ChambonDepartment of Chemistry, University of Liverpool, Crown Street, Liverpool, L69 7ZD, UK. srannard@liverpool.ac.uk.
Neill LiptrottCentre of Excellence in Long-acting Therapeutics (CELT), University of Liverpool, Liverpool, L7 3NY, UK.ORCID 0000-0002-5980-8966
Tom O McDonaldDepartment of Chemistry, University of Liverpool, Crown Street, Liverpool, L69 7ZD, UK. srannard@liverpool.ac.uk.ORCID 0000-0002-9273-9173
Megan NearyMaterials Innovation Factory, University of Liverpool, Crown Street, L69 7ZD, UK.
Andrew OwenMaterials Innovation Factory, University of Liverpool, Crown Street, L69 7ZD, UK.
Caren Freel MeyersDepartment of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, 725 North Wolfe St., Baltimore, MD, 21205, USA.
Steve P RannardDepartment of Chemistry, University of Liverpool, Crown Street, Liverpool, L69 7ZD, UK. srannard@liverpool.ac.uk.ORCID 0000-0002-6946-1097
University of Liverpool · GBJohns Hopkins University · US

Funding

NIAID NIH HHS R01 AI134091
6 · The paper itself

Abstract

Long-acting drug delivery is a growing area of interest as it overcomes many challenges related to patient adherence to therapy and the pill burden associated with chronic illness. Injectable formulations are becoming more common and drug-releasing implants also provide several opportunities. Highly water soluble drug compounds are poor candidates for long-acting delivery. Here, the water-soluble nucleoside reverse transcriptase inhibitor emtricitabine (FTC) has been used as a novel A-B monomer in step-growth polymerisation with chloroformate functional C

Indexed as

Anti-HIV AgentsHIV InfectionsProdrugsDNA-Directed RNA PolymerasesEmtricitabineHumansNucleosidesPolymersReverse Transcriptase InhibitorsWaterAnti-HIV AgentsDNA-Directed RNA PolymerasesEmtricitabineNucleosidesPolymersProdrugsReverse Transcriptase InhibitorsWater

Identifiers

PMID35604111
PMCPMC9199480
OpenAlexW4282943461

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.